Navigation Links
FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Date:4/25/2011

aths were reported during the study. Four percent of patients treated with 300 mg/day and 10 percent treated with 250 mg/day discontinued treatment due to adverse events. The only adverse event leading to withdrawal in more than one patient was rash (n=1 in 300mg/day, n=7 in 250 mg/day group).

Treatment-emergent adverse events were reported by 53 percent and 61 percent of patients in the 300 mg/day and 250 mg/day groups, respectively. The most common adverse events occurring in at least 5 percent of patients in either the 300 mg/day or 250 mg/day treatment group, respectively, were: headache (26 and 28 percent), dizziness (11 and 9 percent), rash (4 and 11 percent), nasopharyngitis (6 and 6 percent), nausea (5 and 5 percent), somnolence (4 and 5 percent) and insomnia (0 and 5 percent).

About LamictalXRLamictal XR Extended-Release Tablets are approved in the U.S. as adjunctive therapy for partial seizures and primary generalized tonic-clonic seizures in patients 13 years and older.  

Safety and effectiveness of Lamictal XR for use in patients less than 13 years of age have not been established.

Important Safety InformationPrescription Lamictal XR Extended-Release Tablets are not for everyone. LamictalXR may cause a serious skin rash that may cause patients to be hospitalized or to stop LamictalXR; it may rarely cause death. There is no way to tell if a mild rash will develop into a more serious reaction. These serious skin reactions are more likely to happen when patients begin taking Lamictal XR, within the first two to eight weeks of treatment. But it can happen in people who have taken Lamictal XR for any period of time. Children between 2 to 16 years of age have a higher chance of getting this serious skin reaction while taking lamotrigine. Lamictal XR is not ap
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
2. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
3. FDA Approves New Medical Device for Form of Brain Cancer
4. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
5. FDA Approves Horizant To Treat Restless Legs Syndrome
6. FDA Approves New Treatment for Rare Form of Thyroid Cancer
7. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
8. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
9. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
10. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
11. FDA Approves Gadavist for Central Nervous System Scans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  A new analysis of Centers for ... enrollment data shows that 81 percent of seniors chose ... extra discounts at certain pharmacies. The findings were released ... plans are now the foundation of Medicare Part D," ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... Holdings, Inc. (OTC Bulletin Board: ADLS ), announced ... discussing the Company,s 2010 third quarter financial results on Friday, ... Ph.D., Chairman & Chief Executive Officer, as well as other ... on the Company. A press release reporting the 2010 third ...
... 2010 Neuraltus Pharmaceuticals, a privately held biopharmaceutical ... that address critical unmet needs, primarily in the ... was awarded three grants totaling $733,437 ... (QTDP).  The grants are being provided under section ...
Cached Medicine Technology:Advanced Life Sciences to Host 2010 Third Quarter Financial Results Conference Call and Webcast 2Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP) 2Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP) 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... scientists have developed a hormone-free contraceptive pill for men they ... tablet, developed by researched at King's College London, can be ... being able to impregnate a woman. However, his fertility would ... edition of Daily Mail. ,Contraceptive pills available in ...
... Jai Prakash Narayan Apex Trauma Center (JPNATC), which was conceived ... patients of road accidents. ,The All India ... sq meters, seven-storey hospital with 200 beds, including 16 ICU ... dry run on Monday by shifting 55 'not so critical ...
... unearthed clues,from studies on dragonflies, that may help in ... revealed that when dragonflies are infected with certain parasites ... similar to the Type -2 diabetes seen in humans. ... studies may hold the key to understanding the underlying ...
... the Department of Molecular, Cellular and Developmental Biology (MCDB) ... awarded// the prestigious 2006 E. B. Wilson Medal, ... scientific research in cell biology. ,The medal ... assembly, maintenance and function of fine, hair-like cell organelles, ...
... brain protein known to underlie a form of Parkinson's disease ... branching of neurons//, researchers have found. They have pinpointed the ... gene called LRRK2 and how it affects neurons, ultimately leading ... to the pathology of PD, and loss of connections among ...
... in 2002 to work in the National Health Service but was ... incurable brain disease, will now be// able to return to India ... ,Kaushik Chatterjee, a doctor from Kolkata, came to Britain in ... was appointed senior house officer in elderly care at Sunderland Royal ...
Cached Medicine News:Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 2Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 3Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 4Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 5Health News:Parkinson's Mutation Stunts Neurons 2Health News:Ailing Indian doctor in Britain to return to Kolkata 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: